High Court's Superficial Analysis In Biosimilars Ruling

Law360, New York (June 15, 2017, 4:43 PM EDT) -- In the last 12 months, including the U.S. Supreme Court’s landmark pharmaceutical decision in Sandoz Inc. v. Amgen Inc., 582 U.S. ____ (June 12, 2017), the Supreme Court has reversed the Federal Circuit seven out of eight times in patent cases.[1] This term alone, the Federal Circuit was 0-6. Patent owners are working harder and harder to protect their investment in innovation, especially in the biotech arena. The Supreme Court arrived at the outcome many in the industry were expecting, given that the Federal Circuit’s decision...
To view the full article, register now.